Printed From BioPortfolio.com

Kyn Announces $49M Series A Capital to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways

11:37 EST 14 Dec 2017 | Drug Discovery Development

News

Kyn Therapeutics is focused on making the power of immunotherapy work for every patient with cancer.

Contributed Author:

Kyn Therapeutics

Topics:

Biotech

Original Article: Kyn Announces $49M Series A Capital to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways

More From BioPortfolio on "Kyn Announces $49M Series A Capital to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topic

Cancer
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches